000roulette| Another Phase 3 trial of semiglutide reaches the endpoint, Novo Nordisk (NVO.US) plans to submit regulatory application in 24 years

Zhitong Financial APP learned that recently, Novo Nordisk (NVO000roulette.US) announced at the European Kidney Association (ERA) meeting000rouletteThe latest results of the FLOW clinical phase 3 trial of its blockbuster therapy Ozempic(semaglutide, semaglutide) were reported. According to analysis, Ozempic met the primary endpoint and all secondary endpoints of the trial. Compared with placebo, Ozempic reduced the risk of major cardiovascular events by 18% and the risk of death from any cause by 20%, in patients with chronic kidney disease (CKD) and type 2 diabetes. It is noteworthy that Novo Nordisk plans to submit regulatory applications for Ozempic label extension to the United States and the European Union in 2024.

according to000rouletteUnderstand that the FLOW clinical trial is a randomized, double-blind, placebo-controlled clinical trial designed to examine the dose of 1000rouletteThe effect of..0 mg subcutaneous injection of Ozempic compared to placebo as an adjunct to standard care in preventing the progression of renal injury and the risk of renal and cardiovascular death in patients with CKD and type 2 diabetes.

Ozempic is a GLP-1 receptor agonist that stimulates the production of insulin. The weekly injectable version of the therapy was approved by the FDA in 2017 to treat type 2 diabetes. It was re-approved by the FDA in January 2020 to reduce the risk of major adverse cardiovascular events (MACE), such as heart attack, stroke or death, in adult patients with type 2 diabetes and known heart disease.

According to information on the ClinicalTrials.gov website, Novo Nordisk will also initiate a phase 2 trial to examine the effects of three drugs, including semigroutide, on liver function, liver fibrosis and alcohol intake in patients with alcohol-related liver disease. According to industry media STAT, this may be the first time the company has examined the impact of GLP-1 drugs on addiction.

According to estimates by the World Health Organization (WHO), approximately 422 million people around the world suffer from diabetes, a disease often caused by the body's inability to produce enough insulin or its inability to properly use the insulin synthesized by the body. Therefore, the ability of these patients to regulate blood sugar will be greatly affected. In addition, people with type 2 diabetes also have a higher risk of developing other diseases. For example, people with type 2 diabetes have a 2-4 times higher risk of developing cardiovascular disease than healthy people, and approximately 40% of people with type 2 diabetes have CKD.